https://orcid.org/0000-0001-9830-9126
-
PDF
- Split View
-
Views
-
Cite
Cite
Stefanie Howaldt, Eugeni Domènech, Nicholas Martinez, Carsten Schmidt, Bernd Bokemeyer, on behalf of the AEGIS Trialists, Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial, Inflammatory Bowel Diseases, Volume 28, Issue 3, March 2022, Page 494, https://doi.org/10.1093/ibd/izab224
Close - Share Icon Share
In the article titled “Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial”, the legends for Figures 3 and 4 were incorrect.
The incorrect legends read as follows:
“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population, observed patients). P values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”.
“Figure 4. Patients achieving ≥1 and ≥2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). P values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”.
The legends should read as follows:
“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population). P values shown for least-squares mean change from baseline, difference between groups.”.
“Figure 4. Patients achieving ≥1 and ≥2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). P values shown for risk difference between groups.”.
These errors have been corrected online and in print.
